

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1459 Alexandrix, Virginia 22313-1450

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/840,197	04/23/2001	Abe Widra	383939.00002	5490	
7590 01/16/2004			EXAMI	INER	
Harvey S. Kauget			SAUCIER, SANDRA E		
Holland & Knight LLP 100 N. Tampa Street			ART UNIT PAPER NUM		
Suite 4100			1651		
Tampa, FL 33	6602		DATE MAILED: 01/16/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

رہ	`
~,	•
دک	

		Application No.		Applicant(s)	
Office Action Summary		09/840,197	09/840,197 WIDRA, ABE		
		Examiner		Art Unit	
		Sandra Saucier		1651	
The MAILING DATE of the	is communication app		sheet with the c	orrespondence ad	ldress
Period for Reply				O) 50011	
A SHORTENED STATUTORY THE MAILING DATE OF THIS Extensions of time may be available unde after SIX (6) MONTHS from the mailling d If the period for reply specified above, is If NO period for reply is specified above, Failure to reply within the set or extended Any reply received by the Office later thar earned patent term adjustment. See 37 C	COMMUNICATION. In the provisions of 37 CFR 1.1 ate of this communication. In this thirty (30) days, a replice maximum statutory period of period for reply will, by statute three months after the mailing	36(a). In no event, howe y within the statutory min will apply and will expire : a, cause the application to	ever, may a reply be tin imum of thirty (30) day SIX (6) MONTHS from b become ABANDONE	nely filed s will be considered timel the mailing date of this or D (35 U.S.C. § 133).	y. ommunication.
1) Responsive to communic	cation(s) filed on 21 N	lovember 2003.			
2a)⊠ This action is FINAL .	2b)☐ This	action is non-fina	l.		
3) Since this application is in closed in accordance with	n condition for allowa h the practice under <i>E</i>	nce except for for Ex <i>part</i> e Quayle, '	mal matters, pro 1935 C.D. 11, 4	osecution as to the 53 O.G. 213.	e merits is
Disposition of Claims					
4) Claim(s) 1-3 and 9-20 is/	are pending in the ap	plication.			
4a) Of the above claim(s)		n from considerat	ion.		
5) Claim(s) is/are allo					
6) Claim(s) <u>1-3</u> is/are reject					
7) Claim(s) is/are ob 8) Claim(s) are subje		or election require	ment		
	ect to restriction and/c	or election require	illone.		
Application Papers	taal ta buutha Fugusina				
9)☐ The specification is objec 10)☐ The drawing(s) filed on _			ected to by the l	Examiner.	
Applicant may not request t					
Replacement drawing shee					FR 1.121(d).
11) The oath or declaration is					
Priority under 35 U.S.C. §§ 119 a					
12) Acknowledgment is mad	e of a claim for foreig	n priority under 35	5 U.S.C. § 119(a	ı)-(d) or (f).	
a) All b) Some * c)		la hava baan raad	in cod		
1. ☐ Certified copies of 2. ☐ Certified copies of	the priority document	is have been rece is have been rece	iveu. ived in Applicati	on No	
3. Copies of the certi	fied copies of the prio	rity documents ha	ave been receive	ed in this National	Stage
application from th * See the attached detailed	e International Burea			2d	
13) Acknowledgment is made	of a claim for domest	ic priority under 3	5 U.S.C. § 119(e) (to a provisiona	l application)
since a specific reference v	was included in the fir	st sentence of the	specification or	r in an Application	Data Sheet.
37 CFR 1.78. a) ☐ The translation of the	e foreign language pro	ovisional applicati	on has been red	eived.	
14) Acknowledgment is made reference was included in t	of a claim for domest	ic priority under 3	5 U.S.C. §§ 120	and/or 121 since	a specific CFR 1.78.
Attachment(s)					
1) Notice of References Cited (PTO-89		4) 🔲	Interview Summary	(PTO-413) Paper No	(s)
Notice of Draftsperson's Patent Drav Information Disclosure Statement(s)			Notice of Informal F Other: .	Patent Application (PT)	J-152)

Application/Control Number: 09/840,197 Page 2

Art Unit: 1651

DETAILED ACTION

Claims 1-3, 9-20 are pending. Claims 1-3 are considered on the merits. Claims 9-20 are withdrawn from consideration as being drawn to a non-elected invention.

Claim Rejections - 35 USC § 112 INDEFINITE

Claims 1–3 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1 reads "a physiologically balanced electrolyte solution". This does not appear to be a term of art. In what respect is the electrolyte solution physiologically balanced? Osmotically? With respect to amino acid concentrations? With respect to the types of electrolytes? As compared to rabbit or human physiology? As compared to the physiology of plasma or serum or blood or interstitial fluid or gastric fluid? Please point to the definition in the specification for clarification of this term.

Claims 1–3 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claims contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor at the time the application was filed, had possession of the claimed invention.

There does not seem to be either a definition or literal support in the specification for the new insertion "physiologically balanced electrolyte solution".

Claim Rejections - 35 USC § 102

Claims 1–3 remain rejected under 35 U.S.C. 102(b) as being clearly anticipated by Ewald *et al.* [IDS].

Ewald *et al.* disclose a composition comprising a soluble component of keratin obtained by hydrogen peroxide hydrolysis in sterile saline. α -keratose would at least be one component of the solution disclosed by Ewald *et al.*.

Sterile saline is considered to be a physiologically balanced electrolyte solution

Application/Control Number: 09/840,197 Page 3

Art Unit: 1651

since sterile saline is 0.14M which is the physiological electrolyte concentration of plasma and has been used extensively in the prior art as a carrier for intravenously administered drugs.

Response to Arguments

Applicant's arguments filed 11/21/03 have been fully considered but they are not persuasive.

Applicant argues that it is not necessarily true that α -keratose would be a component of the composition of Ewald $et\ al.$ since they never demonstrated the sulfur-bearing alpha-linked amino acid chains from the complex mixture of oxidized, sulfonated peptides in their soluble hydrolyzate. Please note that it is applicant who must demonstrate the absence of α -keratose in the cited composition. The Patent and Trademark Office is not equipped to conduct experimentation in order to determine whether or not applicants' composition differs and, if so, to what extent from the composition discussed in the reference. Accordingly, it has been established that the prior art composition, which been produced from the same source material and shares the property of being used as a plasma extender demonstrates a reasonable probability that it is either identical or sufficiently similar that whatever differences exist are not patentably significant. Therefore, the burden of establishing novelty by objective evidence is shifted to applicants.

Merely because an inherent component of a known composition is not disclosed in a reference does not make the known composition patentable. The known composition possesses inherent components which might not be precisely disclosed in the reference.

The composition of Ewald *et al.* is argued to be 84% gamma-keratose, which is toxic. This may be true, however, please note that applicant's composition claim is not closed to further components in the composition, rather the claim language is open "comprising". Thus, the arguments are not commensurate in scope with the claims and are, therefore, not persuasive.

Conclusion

Applicant's amendment necessitated the new grounds of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a).

Application/Control Number: 09/840,197

Art Unit: 1651

Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1651. The supervisor for 1651 is M. Wityshyn, (703) 308-4743. The normal work schedule for Examiner Saucier is 8:30 AM to 5:00 PM Monday and Tuesday and 8:30 AM to noon on Wednesday.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sandra Saucier whose telephone number is (571) 272–0922. Status inquiries must be directed to the Customer Service Desk at (703) 308–0197 or (703)–308–0198. The number of the Fax Center for the faxing of official papers is (703) 872–9306.

Sandra Saucier Primary Examiner Art Unit 1651

January 12, 2004